UTMD

UTMD is a rare, high-quality small-cap: 57.1% gross and 29.3% net margins, $85.8M cash (≈37% of the $232M market cap), zero long-term debt, and liabilities/equity of just 0.03x. Management returned $8.4M in buybacks (retiring 4.5% of shares) plus $4.0M in dividends in 2025 while still growing the cash balance — a genuinely shareholder-friendly, self-funding model. Stripping out cash, the enterprise value is ~$146M against $11.3M net income (≈13x EV/earnings), which is undemanding for a business this profitable and this financially unbreakable. On headline P/E of 20.9 it looks fully priced, but the cash-adjusted view is where the value sits.

The problem is the top line. Revenue has fallen every year since the FY2022 peak of $52.3M — to $50.2M, $40.9M, and now $38.5M (-5.8% YoY) — and net income has followed, from $16.5M to $11.3M (-18.7% YoY). The MD&A attributes the 2025 $2.4M decline to three buckets: PendoTECH OEM (-$2.3M, 96% of the drop, an OEM relationship that looks largely gone), the China Deltran distributor that cancelled a supposedly non-cancellable order and forced a $0.4M receivable write-off, and worldwide Filshie (-$0.7M). Some of this is arguably one-off — and domestic direct Filshie actually grew +11% — but two of the three drivers point to eroding OEM/distributor channels rather than temporary noise, and R&D is a tiny $668K (down 17.8%), so there's no visible organic growth engine to replace lost revenue.